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Introduction
The major known familial breast cancer predisposition
genes BRCA1 and BRCA2  are involved in DNA repair
[1]. The ataxia-telangiectasia mutated (ATM) gene product
functions in the double-strand break repair pathway [2],
and there is evidence to suggest that some ATM gene
ATM = ataxia-telangiectasia mutated gene; CI = confidence interval; OR = odds ratio; PCR = polymerase chain reaction.
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Abstract
Background: There is evidence that certain mutations in the double-strand break repair pathway
ataxia-telangiectasia mutated gene act in a dominant-negative manner to increase the risk of breast
cancer. There are also some reports to suggest that the amino acid substitution variants T2119C
Ser707Pro and C3161G Pro1054Arg may be associated with breast cancer risk. We investigate the
breast cancer risk associated with these two nonconservative amino acid substitution variants using a
large Australian population-based case–control study.
Methods: The polymorphisms were genotyped in more than 1300 cases and 600 controls using
5′ exonuclease assays. Case–control analyses and genotype distributions were compared by
logistic regression.
Results: The 2119C variant was rare, occurring at frequencies of 1.4 and 1.3% in cases and controls,
respectively (P = 0.8). There was no difference in genotype distribution between cases and controls
(P = 0.8), and the TC genotype was not associated with increased risk of breast cancer (adjusted
odds ratio = 1.08, 95% confidence interval = 0.59–1.97, P = 0.8). Similarly, the 3161G variant was no
more common in cases than in controls (2.9% versus 2.2%, P = 0.2), there was no difference in
genotype distribution between cases and controls (P = 0.1), and the CG genotype was not associated
with an increased risk of breast cancer (adjusted odds ratio = 1.30, 95% confidence interval =
0.85–1.98, P = 0.2). This lack of evidence for an association persisted within groups defined by the
family history of breast cancer or by age.
Conclusion: The 2119C and 3161G amino acid substitution variants are not associated with
moderate or high risks of breast cancer in Australian women.
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mutations increase the risk of breast cancer. Studies of
families with ataxia-telangiectasia linked to the ATM
region report an average fourfold elevated frequency of
breast cancer among female obligate heterozygote ATM
gene mutation carriers [3]. In addition, ATM mutations
with dominant-negative effects have been detected in a
proportion of Australian multiple-case breast cancer
families [4].
It has been suggested that some ATM missense variants
may be more common in breast cancer cases selected
for first-degree family history and early age at onset [5].
Furthermore, the T2119C Ser707Pro variant [5–7] and
the β-adaptin domain C3161G Pro1054Arg variant [8]
have been reported to be breast cancer related. These
findings were based on small studies of less than 150
cases or controls, with the exception of one large study
of 1000 cases and 500 controls [6], and the confidence
intervals of risk estimates are wide. We have undertaken
a study to investigate the breast cancer risk associated
with these two nonconservative amino acid substitution
variants using a large Australian population-based case–
control study of more than 1300 cases and 600 con-
trols, more than one-half of whom were aged younger
than 40 years.
Materials and methods
Subjects
The Australian Breast Cancer Family Study, a population-
based, age-stratified, case–control–family study of first
primary invasive breast cancer in women younger than age
40 years was carried out in Melbourne and Sydney from
1992 to 1995 [9–11]. The study was extended from 1996
to 2000 to also include women up to age 59 years [10].
Cases were women with a diagnosis of a first primary
breast cancer identified through the Victorian and New
South Wales cancer registries. Controls were women
without breast cancer selected from the electoral roll (adult
registration for voting is compulsory in Australia) using
stratified random sampling, frequency-matched for age.
Cases and controls were administered a questionnaire to
record the family history of cancer and other known or
potential risk factors for breast cancer. With the subjects’
permission, all living parents, aunts, grandparents, and
adult siblings were asked to participate, and were admin-
istered the same risk-factor questionnaire [10,11]. Ances-
try was assessed by an open-ended question, and from
the country of birth of the respondents, their parents and
their grandparents. The great majority of the subjects’
parents and grandparents were born in Australia, the
British Isles or Western Europe. In subanalyses restricted
to Caucasian women, subjects either with any Australian
aboriginal, Torres Strait Islander or Maori heritage or with
any country of birth in the South Pacific, Indian Ocean,
Caribbean islands or Asia were excluded.
The family history of cancers was systematically collected
from each case and each control, and included the cancer
history of all of their first-degree and second-degree rela-
tives. This history was subsequently checked with each
living relative at the time of their interview. A family history
of breast cancer was defined as having at least one first-
degree or second-degree relative with breast cancer. Veri-
fication of all cancers reported by subjects and their
relatives was sought through personal interview, cancer
registries, pathology reports, hospital records, clinicians
and death certificates.
Subjects participating in the study conducted from 1996
to 2000 were asked for information on the number of X-ray
examinations or radiation treatments they had undergone,
and their age at first X-ray examination or radiation treat-
ment. Exposure to X-rays/ionizing radiation was considered
as a yes/no variable, irrespective of age at first exposure.
Interviews were conducted for 1579 of 2304 eligible
cases (68.5%) and for 1021 of 1531 eligible controls
(66.7%). Attrition of cases was due to death (1.8%), to
refusal by the surgeon (8.5%), to refusal by the proband
(16.4%), to nonresponse by the surgeon (1.3%), to non-
response by the proband (1.2%) and to failure to locate
the proband (2.3%). Attrition of controls was due to
refusal (28.2%) and to nonresponse (5.1%). Not all inter-
viewed cases and controls elected to donate a blood
sample for DNA studies. Genotyping for the T2119C
variant was carried out on the 1331 cases (84% of those
participating) and 649 controls (64% of those participat-
ing) with DNA available at the time of analysis, and subse-
quently for the C3161G variant on 1453 cases (92% of
those participating) and 793 controls (78% of those par-
ticipating). PCR success rates were greater than 99%.
The average age ± standard deviation of cases and con-
trols was 39.6 ± 9.0 and 42.0 ± 8.8 years, respectively,
for individuals genotyped for the T2119C variant, and was
41.7 ± 8.7 and 40.1 ± 8.9 years, respectively, for individu-
als genotyped for the C3161G variant.
Approval of this study was obtained from the ethics com-
mittees of The University of Melbourne, the New South
Wales Cancer Council, The Anti-Cancer Council of Victo-
ria, and The Queensland Institute of Medical Research.
Molecular analysis
Collection of peripheral blood and DNA extraction have
been described previously [12]. The ATM variants were
detected using the ABI Prism 7700 Sequence Detection
System 5′ exonuclease assay (Perkin-Elmer Corp., Foster
City, USA), using the methodology as described previ-
ously [13]. The T2119C variant was detected using the
forward and reverse primers 5′-CGCTGTCTTCTGGGT-
TTATCAG-3′ and 5′-CCTTCCTAACAGTTTACCAAAGT-
TGA-3′, and the probes 5′-FAM-CTGAATAATTACTCAt-Page 3 of 6
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CTGAGGTGAGAT-TAMRA-3′ (T allele) and 5′-VIC-TCT-
GAATAATTACTCAcCTGAGGTGA-TAMRA-3′ (C allele).
The C3161G variant was detected using the forward and
reverse primers 5′-CTCTATTTCATATTTAACCACAGTT-
CTTTTC-3′ and 5′-GTCTTTTCCCATTACATTAAGAA-
TGG-3′, and the probes designed to the complement
strand 5′-FAM-CCCATTTTGAATAAgGATCAGCCTA-
CGG-TAMRA-3′ (C allele) and 5′-VIC-CCCATTTTGAATA-
AcGATCAGCCTACGG-TAMRA-3′ (G allele).
Statistical methods
Allele frequencies were estimated and compared assum-
ing that alleles within an individual were independent bino-
mial variables. The Hardy–Weinberg equilibrium
assumption was assessed for defined groups using
maximum likelihood methods by comparing the observed
numbers of different genotypes with those expected under
Hardy–Weinberg equilibrium in that group. The odds ratio
(OR) and the 95% confidence interval (CI) were calcu-
lated using unconditional logistical regression, with and
without adjustment for measured risk factors. We used
stratified analysis to determine whether the genotype-
breast cancer association varied by age <40 or
≥40 years, by family history, by menopausal status and by
chest exposure to X-rays and/or ionizing radiation. All sta-
tistical tests and P values were two tailed and, following
convention, statistical significance was taken as a nominal
P < 0.05. SPSS (version 10.0; SPSS Australia Pty Ltd),
Epi-Info 6 (freeware; http://www.cdc.gov/epiinfo/ei6.htm)
and Ottutil software (freeware; http://linkage.rockefeller.
edu/ott/linkutil.htm) were used for the statistical analyses.
Results
Table 1 presents the ATM T2119C and C3161G allele
and genotype frequencies for cases and controls overall,
and stratified by family history of breast cancer (reported
first-degree or second-degree relative) or by age
(<40 years versus ≥40 years). There was no evidence of
deviation from Hardy–Weinberg equilibrium for either
variant, in either cases or controls (P ≥ 0.3).
The 2119C variant was rare, occurring at frequencies of
1.4 and 1.3% in cases and controls, respectively (P = 0.8).
There was no difference in genotype distribution between
cases and controls (P = 0.8), and the TC genotype was
not associated with an increased risk of breast cancer
(adjusted OR = 1.08, 95% CI = 0.59–1.97, P = 0.8). Simi-
larly, the 3161G variant was no more common in cases
than in controls (2.9% versus 2.2%, P = 0.2), there was no
difference in genotype distribution between cases and
controls (P = 0.1), and the CG genotype was not associ-
ated with an increased risk of breast cancer (adjusted OR
= 1.30, 95% CI = 0.85–1.98, P = 0.2).
This lack of evidence for an association persisted within
groups defined by family history of breast cancer or age
(Table 1) (P > 0.2), for both family history and age (data
not shown) (P > 0.2), or for menopausal status (post-
menopausal status defined as cessation of menstrual
periods for 1 year or more; data not shown) (P > 0.6).
Crude risk estimates were similar to those adjusted for
measured potential confounders (Table 1). ORs were also
little different when adjusted only for the subset of factors
that might influence risk estimates due to the possibility of
distorted control selection (namely, age, country of birth,
state, education and marital status), in which case the
ORs became 1.16 (95% CI = 0.64–2.09) and 1.33 (95%
CI = 0.88–2.01) for the 2119 TC and 3161 CG geno-
types, respectively.
Results were similar when analyses were restricted to
women of Caucasian ancestry. The adjusted OR was 1.14
(95% CI = 0.60–2.14) for the 1185 cases and 573 con-
trols genotyped for the T2119C variant (P = 0.7), and was
1.37 (95% CI = 0.87–2.17) for the 1296 cases and 660
controls genotyped for the C3161G variant (P = 0.2). The
ORs were also little different when analyses were carried
out excluding cases known to carry a deleterious mutation
in BRCA1 or BRCA2 (32 and 34 individuals for T2119C
and C3161G, respectively; data not shown).
Since ATM homozygote and heterozygote mutation carri-
ers are known to exhibit radiosensitivity, and radiation
exposure is associated with risk of breast cancer, we
studied the T2119C and C3161G genotyped cases (244
and 263 individuals, respectively) and controls (87 and
105 individuals, respectively) who reported exposure to
chest X-rays and/or ionizing radiation. Although the fre-
quency of the variant genotype was numerically greater in
exposed cases compared with exposed controls for both
variants, this difference was not significant for either
T2119C (2.5% versus 1.1%, OR = 2.17, 95% CI =
0.26–18.27,  P = 0.5) or C3161G (3.8% versus 2.9%,
OR = 1.34, 95% CI = 0.36–4.98, P = 0.7).
Finally, we investigated the possibility that the risk of
breast cancer may be modified by a combination of the
two variants. There were no individuals who were het-
erozygous for both variants and, compared with the 2119
TT/ 3161 CC reference group, there was no increased
risk of breast cancer associated with having the 2119 TC
genotype alone (OR = 1.11, 95% CI = 0.62–1.98,
P = 0.7), the 3161 GC genotype alone (OR = 1.36, 95%
CI = 0.88–2.13, P = 0.2), or either variant (i.e. the 2119
TC genotype or the 3161 CG genotype) (OR = 1.27,
95% CI = 0.89–1.81, P = 0.2).
Discussion
The 2119C variant has been reported by three studies to
be more common in breast cancer cases than in controls
[5–7]. Using subsamples from a population-based,
case–control study carried out in three different
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.geographic areas of the United States, Teraoka et al. [5]
observed the 2119C variant in 6/142 (4.2%) cases
selected for diagnosis before the age of 35 years, or diag-
nosis before the age of 45 years and reporting a first-
degree family history of breast cancer, and in 1/81 (1.2%)
controls of similar age. This translates to an OR (95% CI)
of 3.5 (0.4–29.9). A Georgetown study of 43 breast
cancer patients and 43 ethnically matched controls,
sampled at a medical centre and a clinic, respectively,
reported the 2119C variant in a single case only (2.3%)
[7]. A large study of individuals from the Lower Saxony
region of Germany reported heterozygote frequencies of
2.8% in 1000 unselected hospital-based breast cancer
patients (median age, 57 years) and of 1.2% in 500
random blood donor controls, translating to an OR of 2.4
(95% CI = 1.0–5.6) that was at best marginally different
from unity [6]. Our larger Australian population-based
case and control samples were frequency-matched for
age, and our study found no evidence for such an
increased risk, before or after adjustment for measured
risk factors, or in the subset of Caucasian individuals. Our
results also suggest that the risk associated with the
2119C allele is unlikely to be limited to younger women
reporting a family history, as reported by Teraoka et al. [5].
The previous study reporting breast cancer risk associated
with the 3161G variant used both a case–control and
sibpair design [8]. The heterozygote genotype was
observed in 2/57 (3.5%) sporadic breast cancer cases, in
4/126 (3.2%) controls, and in 9/66 (13.6%) affected cases
identified from sibpairs with breast cancer. The OR within
the latter group was reported to be 4.5 (95% CI =
1.2–20.5). The present study found no evidence for such an
effect. Although the frequency of the 3161 heterozygote
genotype is nominally greater in Australian cases compared
with controls, overall or within strata defined by family
history or age, this difference is not statistically significant.
Furthermore, the frequency of heterozygotes in our sub-
group of 49 cases reporting affected sibs (2.0%) was
decreased relative to controls, and was not statistically sig-
nificantly different (P = 0.06) to the sibship cases of Larson
et al. [8]. Interestingly, the Georgetown study of 43 breast
cancer patients and 43 ethnically matched controls [7] also
found no evidence to suggest that the 3161G variant is
associated with breast cancer, reporting the 3161G variant
at similar frequencies among cases (two heterozygotes) and
controls (one heterozygote and one homozygote).
Given the observed frequencies of greater than 1% for the
variant alleles in our large control sample (n > 600), and
no large differences in allele frequency between the case
and control groups, we believe these variants should be
considered nonpathogenic polymorphisms. These variants
are unlikely to be associated with even moderate risks of
breast cancer, although we cannot exclude the possibility
that they may be associated with weaker risks.
The present study was of sufficient size to have 80%
power at the 0.05 level of significance to detect an OR of
2.1 or more for the T2119C variant and an OR of 1.8 or
more for the C3161G variant. Even if the observed OR
point estimates of 1.1 and 1.3 are true, however, the rarity
of the variants is such that the population-attributable risks
associated with them would be in the order of only
0.3–1%. We also cannot exclude a modest increased risk
in women exposed to radiation, despite having genotyped
more than 1900 women. Evaluations of gene–environment
interaction require much larger sample sizes, particularly
given the rarity of exposure to high-level radiation, and the
likelihood of substantial misclassification of both high-level
and low-level radiation exposure due to retrospective
exposure assessment. Large cohort studies of radiation-
exposed women would be needed to assess the associa-
tion of ATM gene variants with breast cancer risk in such
women, but the value of such studies from a population
health perspective is questionable given the rarity of both
genotype and exposure.
Conclusion
We found no evidence that the ATM 2119C and 3161G
amino acid substitution variants are associated with mod-
erate or high risks of breast cancer in Australian women.
Although weak risks cannot be excluded, our results
suggest that the population-attributable risk associated
with them would be negligible.
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